Reviewer’s report

Title: Determination of Parecoxib and Valdecoxib in Rat Plasma by UPLC-MS/MS and its Application to Pharmacokinetics Studies

Version: 1 Date: 26 Oct 2019

Reviewer: Enayatollah Seydi

Reviewer's report:

Comments to the Author
The manuscript by Chen et al shows the Establishment of Quantitative Methodology in Parecoxib and Its Main Metabolite Valdecoxib Analysis and the Further Application of Its Pharmacokinetics in Rat.

Comments:

♣ The title of the article should be revised, and it's long.

♣ At the end of the introduction the purpose is not well mentioned.

♣ The code of ethics is not mentioned in the Pharmacokinetic study section.

♣ How were the doses and times selected? Are they based on the literature or on epidemiologic/exposure studies?

♣ Write the names of the compounds in full in the tables.

♣ Significant in the tables are not mentioned.

♣ The discussion of the article is not well written.

♣ The English language needs to be revised.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

Noo

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal